000108505 001__ 108505
000108505 005__ 20211122153226.0
000108505 0247_ $$2doi$$a10.1021/acs.inorgchem.0c02922
000108505 0248_ $$2sideral$$a122422
000108505 037__ $$aART-2020-122422
000108505 041__ $$aeng
000108505 100__ $$aMármol, I.
000108505 245__ $$aGold(I) and Silver(I) Complexes with 2-Anilinopyridine-Based Heterocycles as Multitarget Drugs against Colon Cancer
000108505 260__ $$c2020
000108505 5060_ $$aAccess copy available to the general public$$fUnrestricted
000108505 5203_ $$aA series of gold(I) and silver(I) derivatives with N- or S-donor ligands derived from 2-anilinopyridine has been synthesized and characterized. The mononuclear structure of [Au(L1)(PPh3)](TfO) (1a) and [Au(L2)(PPh3)](TfO) (1b) was confirmed by X-ray diffraction studies, as well as the dinuclear structure in the case of [Ag(TfO)(L1)]2 (4a). Most of the complexes are cytotoxic against a model of colorectal adenocarcinoma (Caco-2 cell line) and breast adenocarcinoma cancer cell lines (MCF-7). [Au(L1)(PPh3)](TfO) (1a) was able to induce caspases 8 and 3 activation, loss of mitochondrial membrane potential, and reactive oxygen species (ROS)-dependent cell death on Caco-2 cells upon 24 h incubation. In addition, the gold complex 1a produced a significant inhibition of the redox enzyme thioredoxin reductase as well as 20S proteasome. However, the silver(I) analogue, [Ag(TfO)(L1)(PPh3)] (2a), induced cell death independent of inhibition of thioredoxin reductase and 20S proteasome, triggered ROS-independent apoptosis mediated by caspase 8 and 3 activation, and loss of mitochondrial membrane potential, which points to a different mechanism of action for both derivatives, dependent on the metal center.
000108505 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B16-R17$$9info:eu-repo/grantAgreement/ES/DGA-FSE/E07-20R$$9info:eu-repo/grantAgreement/ES/ISCIII-CIBERObn/CB06-03-1012$$9info:eu-repo/grantAgreement/ES/MCIU/RED2018-102471-T$$9info:eu-repo/grantAgreement/ES/MINECO/CTQ2016-75816-C2-1-P$$9info:eu-repo/grantAgreement/ES/MINECO/PID2019-104379RB-C21$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2016-75441-R$$9info:eu-repo/grantAgreement/EUR/SUDOE/INTERREG/Redvalue-SOE1-PI-E0123
000108505 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000108505 590__ $$a5.165$$b2020
000108505 591__ $$aCHEMISTRY, INORGANIC & NUCLEAR$$b5 / 45 = 0.111$$c2020$$dQ1$$eT1
000108505 592__ $$a1.348$$b2020
000108505 593__ $$aChemistry (miscellaneous)$$c2020$$dQ1
000108505 593__ $$aPhysical and Theoretical Chemistry$$c2020$$dQ1
000108505 593__ $$aInorganic Chemistry$$c2020$$dQ1
000108505 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000108505 700__ $$aMontanel-Perez, S.
000108505 700__ $$aRoyo, J.C.
000108505 700__ $$0(orcid)0000-0003-0553-0695$$aGimeno, M.C.$$uUniversidad de Zaragoza
000108505 700__ $$0(orcid)0000-0002-3978-1145$$aVillacampa, M.D.
000108505 700__ $$0(orcid)0000-0002-3595-7668$$aRodríguez-Yoldi, M.J.$$uUniversidad de Zaragoza
000108505 700__ $$0(orcid)0000-0003-2457-3674$$aCerrada, E.$$uUniversidad de Zaragoza
000108505 7102_ $$12010$$2760$$aUniversidad de Zaragoza$$bDpto. Química Inorgánica$$cÁrea Química Inorgánica
000108505 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000108505 773__ $$g59, 23 (2020), 17732-17745$$pInorg. chem.$$tInorganic Chemistry$$x0020-1669
000108505 8564_ $$s781817$$uhttps://zaguan.unizar.es/record/108505/files/texto_completo.pdf$$yPostprint
000108505 8564_ $$s1693308$$uhttps://zaguan.unizar.es/record/108505/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000108505 909CO $$ooai:zaguan.unizar.es:108505$$particulos$$pdriver
000108505 951__ $$a2021-11-22-14:00:35
000108505 980__ $$aARTICLE